Scott Bizily Sells 9,810 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 9,810 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the sale, the insider owned 8,617 shares in the company, valued at approximately $103,404. This trade represents a 53.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

4D Molecular Therapeutics Trading Up 0.7%

Shares of NASDAQ FDMT opened at $11.60 on Friday. 4D Molecular Therapeutics, Inc. has a twelve month low of $3.68 and a twelve month high of $12.34. The firm has a 50-day moving average of $9.58 and a two-hundred day moving average of $9.16. The company has a market capitalization of $606.40 million, a price-to-earnings ratio of -4.51 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The business had revenue of $3.05 million during the quarter, compared to analyst estimates of $2.59 million. As a group, research analysts predict that 4D Molecular Therapeutics, Inc. will post -4.14 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on FDMT shares. Royal Bank Of Canada raised their price objective on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, March 19th. Chardan Capital reaffirmed a “buy” rating and set a $26.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Monday, April 20th. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Finally, Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $29.88.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its holdings in shares of 4D Molecular Therapeutics by 17.0% in the first quarter. Bank of America Corp DE now owns 974,173 shares of the company’s stock valued at $9,070,000 after purchasing an additional 141,582 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of 4D Molecular Therapeutics by 13.2% during the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock valued at $48,868,000 after buying an additional 611,276 shares in the last quarter. Exome Asset Management LLC purchased a new position in shares of 4D Molecular Therapeutics during the first quarter valued at $1,216,000. Renaissance Technologies LLC raised its position in 4D Molecular Therapeutics by 12.7% during the first quarter. Renaissance Technologies LLC now owns 578,265 shares of the company’s stock valued at $5,384,000 after buying an additional 65,365 shares during the period. Finally, Sei Investments Co. raised its position in 4D Molecular Therapeutics by 8.9% during the first quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock valued at $120,000 after buying an additional 1,050 shares during the period. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.